

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person* Eansor Norman David		2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ____ Director _____ 10% Owner <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) President-Protein Sciences	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/05/2021		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
8100 SOUTHPARK WAY, A-8			4. If Amendment, Date Original Filed (Month/Day/Year)		
(Street) LITTLETON, CO 80120					
(City)	(State)	(Zip)			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)				Price
Common Stock	02/05/2021		M		14,114	A	\$ 106.59	15,432	D	
Common Stock	02/05/2021		M		18,819	A	\$ 106.59	34,251	D	
Common Stock	02/05/2021		S		6,000	D	\$ 378.2871 (1)	28,251	D	
Common Stock	02/05/2021		S		4,500	D	\$ 379.6249 (2)	23,751	D	
Common Stock	02/05/2021		S		12,833	D	\$ 380.497 (3)	10,918	D	
Common Stock	02/05/2021		S		2,900	D	\$ 381.5155 (4)	8,018	D	
Common Stock	02/05/2021		S		3,700	D	\$ 382.6043 (5)	4,318	D	
Common Stock	02/05/2021		S		1,900	D	\$ 384.1518 (6)	2,418	D	
Common Stock	02/05/2021		S		1,100	D	\$ 385.5918 (7)	1,318	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)	Date Exercisable	Expiration Date				
Stock Options (Right to Buy)	\$ 106.59	02/05/2021		M		14,114	(9)	08/18/2023	Common Stock	14,114	\$ 0	0	D	

Stock Options (Right to Buy)	\$ 106.59	02/05/2021		M			18,819	(9)	08/18/2023	Common Stock	18,819	\$ 0	0	D
Stock Options (Right to Buy)	\$ 125.05							(9)	08/09/2024	Common Stock	11,982		11,982	D
Stock Options (Right to Buy)	\$ 125.05							(10)	08/09/2024	Common Stock	15,976		15,976	D
Restricted Stock Units	(8)							(11)	(11)	Common Stock	2,537		2,537	D
Stock Options (Right to Buy)	\$ 177.32							(11)	08/08/2025	Common Stock	13,550		13,550	D
Stock Options (Right to Buy)	\$ 177.32							(12)	08/08/2025	Common Stock	18,066		18,066	D
Restricted Stock Units	(8)							(13)	(13)	Common Stock	3,151		3,151	D
Stock Options (Right to Buy)	\$ 190.41							(13)	08/07/2026	Common Stock	15,948		15,948	D
Stock Options (Right to Buy)	\$ 190.41							(14)	08/07/2026	Common Stock	21,265		21,265	D
Restricted Stock Units	(8)							(15)	(15)	Common Stock	2,575		2,575	D
Stock Options (Right to Buy)	\$ 267.87							(15)	08/05/2027	Common Stock	11,488		11,488	D
Stock Options (Right to Buy)	\$ 267.87							(16)	08/05/2027	Common Stock	15,318		15,318	D
Stock Options (Right to Buy)	\$ 267.87							(17)	08/05/2027	Common Stock	24,975		24,975	D
Stock Options (Right to Buy)	\$ 267.87							(18)	08/05/2027	Common Stock	24,975.00		24,975.00	D

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Eansor Norman David 8100 SOUTHPARK WAY, A-8 LITTLETON, CO 80120			President-Protein Sciences	

Signatures

/s/ Brenda S. Furlow as Attorney-in-Fact for N. David Eansor pursuant to Power of Attorney previously filed.	02/09/2021
--	------------

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$378.00 to \$378.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$379.03 to \$380.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$380.065 to \$381.055, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$381.095 to \$382.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$382.26 to \$383.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$383.93 to \$384.39, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$385.415 to \$385.77, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (8) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (9) Fully exercisable.
- (10) Options to purchase 3,994 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021.
- (11) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (12) Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.
- (13) Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (14) Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
- (15) Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (16) Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024.
- (17) Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021
- (18) Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.